In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.
about
Neuroprotection in GlaucomaGlaucoma treatment in Australia: changing patterns of therapy 1994-2003.Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics.Calpain activation in experimental glaucoma.5-Hydroxytryptamine1A agonists: potential use in glaucoma. Evidence from animal studies.Treatment of nonarteritic anterior ischemic optic neuropathyAre there any benefits of Betoptic S (betaxolol HCl ophthalmic suspension) over other beta-blockers in the treatment of glaucoma?Treatment of ischemic optic neuropathy.Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.Changing therapeutic paradigms in glaucoma management.Neuroprotection of medical IOP-lowering therapy.Effects of beta-adrenergic receptor antagonists on oxidative stress in purified rat retinal ganglion cells.Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.Progression of retinal nerve fibre layer damage in betaxolol- and timolol-treated glaucoma patients.A new calcium channel antagonist, lomerizine, alleviates secondary retinal ganglion cell death after optic nerve injury in the rat.VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina.
P2860
Q26740388-1666B078-114B-425A-8C26-0ADB4A85B907Q31133573-253AC510-46CF-422D-8020-C417344BE923Q33513713-5819D230-56F7-4591-8A94-935A14459CFDQ33526954-3EECA8AF-FE83-433A-8FCD-0704C0C304C2Q34057619-5CE904E6-58DE-43CA-AAEF-9B153877286AQ34087724-859B3EFE-A436-4416-A13F-ED1E725C385BQ35779199-9490F770-1753-48AC-A7D5-3DE51E222D19Q35932508-8B6F950B-0EE4-4C9A-A9E2-5CFFE7071613Q36048575-7F619489-6A30-468C-98D1-E6CC83504049Q36181220-3EF43D9E-9159-42B7-B542-90A21B095559Q38120187-E39C2F30-C55A-47AC-A31C-6E3BDDF0204CQ40196907-E2D11D2E-371B-4213-81A3-FEF1C3D89492Q41903223-5D12D13B-5F65-491D-879F-09F578BEA56AQ44186882-7475BE80-6741-4897-85CE-CF304B32EFF6Q46986519-5CC6758B-AC77-4D82-BD31-3C7759ABFE4BQ48349620-FEF725CE-CD6A-4377-915D-D8CE17D9F35F
P2860
In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.
@en
In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.
@nl
type
label
In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.
@en
In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.
@nl
prefLabel
In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.
@en
In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.
@nl
P2093
P1433
P1476
In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent
@en
P2093
A K Larsen
C Cazevieille
L DeSantis
N N Osborne
P304
P356
10.1016/S0006-8993(96)01393-5
P407
P577
1997-03-01T00:00:00Z